Ipsen agrees to acquire Memo Therapeutics: the advisors
Ipsen, a globally active biopharmaceutical company listed in Paris and in the U.S., has entered into a definitive share purchase agreement to acquire all issued and outstanding shares of Memo Therapeutics, a late-stage biotech company backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.
In connection with the deal, Lenz & Staehelin advised Ipsen, while Baker McKenzie represented Memo Therapeutics.
The anticipated acquisition is focused on potravitug, which is a Phase II clinical-stage antibody against the BK polyomavirus. The transaction is expected to close during Q3 2026, subject to fulfilment of customary closing conditions.
The Lenz & Staehelin team
Lenz & Staehelin is advising Ipsen in this transaction, jointly with Bredin Prat, Paris. The Lenz & Staehelin team is led by Andreas Rötheli, Federico Trabaldo Togna (both Corporate and M&A) and Floran Ponce (tax) and includes Victor Sellier, Ipek Yüce, Youniss Moussa, Pierrick Sunier and Alexandre Levrat (all corporate and M&A), Victoria Kinson, Maximilien de Ridder and Nicolas Demole (all tax), Sevan Antreasyan and Anne-Laure Laplace (both IP), Benoît Merkt and Valentin Muller (both competition) and Justine Membrez (employment).
Pictured: Federico Trabaldo Togna, Andreas Rötheli, Floran Ponce
The Baker McKenzie team
M&A partner Matthias Trautmann and life sciences partner Julia Schieber led the Baker McKenzie team, which consisted of senior associate Benedikt Rutscheidt (M&A), senior associate Hesam Mirzai (M&A), associate Laksanaporn (Namfon) Chaiyakam (M&A), associate Daniel Jurcevic (M&A), paralegal Natalie Meier (M&A), partner Johanna Moesch (data protection), partner Christoph Stutz (employment), associate Andreas Becker (employment), associate Elena Mani Solanes (IP) as well as trainee lawyers Benjamin Wipfler, Grégory Sarbach, Aleksandra Marchewka, Lukas Bader and Helena Regli.
